Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ.
Buckley, P G
Stallings, R L
Brett, F M
Farrell, M A
AffiliationDepartment of Neuropathology, Beaumont Hospital, Dublin 9, Ireland. email@example.com
Comparative Genomic Hybridization
In Situ Hybridization, Fluorescence
Receptor, Epidermal Growth Factor
Receptor, Platelet-Derived Growth Factor alpha
Receptor, Platelet-Derived Growth Factor beta
Tumor Cells, Cultured
Tumor Markers, Biological
MetadataShow full item record
CitationComparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ. 2012, 318 (17):2245-56 Exp. Cell Res.
JournalExperimental cell research
AbstractDeveloping targeted therapies for high grade gliomas (HGG), the most common primary brain tumor in adults, relies largely on glioma cultures. However, it is unclear if HGG tumorigenic signaling pathways are retained under in-vitro conditions. Using array comparative genomic hybridization and immunohistochemical profiling, we contrasted the epidermal and platelet-derived growth factor receptor (EGFR/PDGFR) in-vitro pathway status of twenty-six primary HGG cultures with the pathway status of their original HGG biopsies. Genomic gains or amplifications were lost during culturing while genomic losses were more likely to be retained. Loss of EGFR amplification was further verified immunohistochemically when EGFR over expression was decreased in the majority of cultures. Conversely, PDGFRα and PDGFRβ were more abundantly expressed in primary cultures than in the original tumor (p<0.05). Despite these genomic and proteomic differences, primary HGG cultures retained key aspects of dysregulated tumorigenic signaling. Both in-vivo and in-vitro the presence of EGFR resulted in downstream activation of P70s6K while reduced downstream activation was associated with the presence of PDGFR and the tumor suppressor, PTEN. The preserved pathway dysregulation make this glioma model suitable for further studies of glioma tumorigenesis, however individual culture related differences must be taken into consideration when testing responsiveness to chemotherapeutic agents.
- Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
- Authors: Kinsella P, Howley R, Doolan P, Clarke C, Madden SF, Clynes M, Farrell M, Amberger-Murphy V
- Issue date: 2012 Mar 10
- Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
- Authors: Azar S, Leventoux N, Ripoll C, Rigau V, Gozé C, Lorcy F, Bauchet L, Duffau H, Guichet PO, Rothhut B, Hugnot JP
- Issue date: 2018 Feb
- Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
- Authors: Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG
- Issue date: 2016 Oct 4
- Copy Number Profiling of Brazilian Astrocytomas.
- Authors: Bidinotto LT, Torrieri R, Mackay A, Almeida GC, Viana-Pereira M, Cruvinel-Carloni A, Spina ML, Campanella NC, Pereira de Menezes W, Clara CA, Becker AP, Jones C, Reis RM
- Issue date: 2016 Jul 7
- Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
- Authors: Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, Brundler MA, Walker DA, Coyle B, Grundy R
- Issue date: 2011 Feb